{"title": "Nat\u00fcrliche Antioxidantien in der Behandlung von Multipler Sklerose", "author": null, "url": "https://ichgcp.net/de/clinical-trials-registry/NCT00010842", "hostname": "ichgcp.net", "description": "Der Zweck dieser Studie ist es, die Wirksamkeit von drei antioxidativen Therapien bei der Behandlung der Symptome von Multipler Sklerose (MS) zu vergleichen.. Register f\u00fcr klinische Studien. ICH GCP.", "sitename": "ichgcp.net", "date": "2001-02-02", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Nat\u00fcrliche Antioxidantien in der Behandlung von Multipler Sklerose\n[National Center for Complementary and Integrative Health (NCCIH)](https://ichgcp.net/de/clinical-trials-registry/research/list?spons=National%20Center%20for%20Complementary%20and%20Integrative%20Health%20%28NCCIH%29)\nStudien\u00fcbersicht\nStatus\nBedingungen\nDetaillierte Beschreibung\nMultiple Sklerose (MS) ist eine immunvermittelte Erkrankung des zentralen Nervensystems, von der \u00fcber 350.000 Amerikaner betroffen sind. T-Lymphozyten, Makrophagen und l\u00f6sliche Entz\u00fcndungsmediatoren verursachen bei MS Demyelinisierung und axonale Sch\u00e4digung. Aktivierte Makrophagen setzen Stickoxid und freie Sauerstoffradikale frei, die bei MS und experimenteller autoimmuner Enzephalomyelitis (EAE) Demyelinisierung und axonale Sch\u00e4digung verursachen. Nat\u00fcrliche Antioxidantien k\u00f6nnen den Verlauf von MS g\u00fcnstig beeinflussen, indem sie oxidative Sch\u00e4den verringern. Chronisch rezidivierende EAE in Mausmodellen ist klinisch und pathologisch n\u00fctzlich, um potenzielle Therapien f\u00fcr MS zu testen.\nDiese Studie wird drei nat\u00fcrliche Antioxidantien auf ihr Potenzial zur Behandlung von MS untersuchen: Ginkgo Biloba, Alpha-Lipons\u00e4ure/essentielle Fetts\u00e4uren und Vitamin E/Selen. Die Wirkungen jedes Regimes werden verglichen, um zu bestimmen, welches Regime bei der Unterdr\u00fcckung von EAE und der Verringerung von Markern f\u00fcr oxidative Verletzungen bei Patienten mit MS am wirksamsten zu sein scheint. Im Rahmen dieser Studie werden zwei kleinere Studien durchgef\u00fchrt. Eine Phase-I/II-Studie bei Patienten mit MS wird bestimmen, ob das gew\u00e4hlte antioxidative Regime die Krankheitsaktivit\u00e4t verringern kann, wie sie mit Gadolinium-verst\u00e4rkter Magnetresonanztomographie nachgewiesen wurde. Die Ergebnisse dieser Studie werden als Grundlage f\u00fcr eine Phase-III-Studie dienen, um die langfristige Wirksamkeit einer Therapie mit nat\u00fcrlichen Antioxidantien bei MS zu bewerten.\nStudientyp\nPhase\n- Phase 2\n- Phase 1\nKontakte und Standorte\nStudienorte\n-\nVereinigte Staaten\n-\nOregon\n-\nPortland, Oregon, Vereinigte Staaten, 97207\n- Oregon Health Sciences University\n-\n-\nTeilnahmekriterien\nZulassungskriterien\nStudienberechtigtes Alter\nAkzeptiert gesunde Freiwillige\nStudienberechtigte Geschlechter\nBeschreibung\nAusschlusskriterien:\n- Schwanger\n- Andere erhebliche Gesundheitsprobleme\nStudienplan\nWie ist die Studie aufgebaut?\nDesigndetails\n- Hauptzweck: Behandlung\n- Zuteilung: Zuf\u00e4llig\nMitarbeiter und Ermittler\nErmittler\n- Hauptermittler: Dr. Dennis Bourdette, VA Medical Center-Brooklyn\nStudienaufzeichnungsdaten\nHaupttermine studieren\nStudienbeginn\nStudienabschluss\nStudienanmeldedaten\nZuerst eingereicht\nZuerst eingereicht, das die QC-Kriterien erf\u00fcllt hat\nZuerst gepostet (Sch\u00e4tzen)\nStudienaufzeichnungsaktualisierungen\nLetztes Update gepostet (Sch\u00e4tzen)\nLetztes eingereichtes Update, das die QC-Kriterien erf\u00fcllt\nZuletzt verifiziert\nMehr Informationen\nBegriffe im Zusammenhang mit dieser Studie\nZus\u00e4tzliche relevante MeSH-Bedingungen\n-\n[Pathologische Prozesse](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pathologic%20Processes)\n-\n[Erkrankungen des Nervensystems](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Nervous%20System%20Diseases)\n-\n[Erkrankungen des Immunsystems](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases)\n-\n[Demyelinisierende Autoimmunerkrankungen, ZNS](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Demyelinating%20Autoimmune%20Diseases%2C%20CNS)\n-\n[Autoimmunerkrankungen des Nervensystems](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Autoimmune%20Diseases%20of%20the%20Nervous%20System)\n-\n[Demyelinisierende Krankheiten](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Demyelinating%20Diseases)\n-\n[Autoimmunerkrankungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Autoimmune%20Diseases)\n-\n[Multiple Sklerose](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Multiple%20Sclerosis)\n-\n[Sklerose](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Sclerosis)\n-\n[Physiologische Wirkungen von Arzneimitteln](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs)\n-\n[Molekulare Mechanismen der pharmakologischen Wirkung](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action)\n-\n[Schutzmittel](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Protective%20Agents)\n-\n[Spurenelemente](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Trace%20Elements)\n-\n[Mikron\u00e4hrstoffe](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Micronutrients)\n-\n[Vitamine](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Vitamins)\n-\n[Antioxidantien](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Antioxidants)\n-\n[Vitamin B-Komplex](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Vitamin%20B%20Complex)\n-\n[Vitamin E](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Vitamin%20E)\n-\n[Thiocts\u00e4ure](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Thioctic%20Acid)\n-\n[Selen](https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Selenium)\nAndere Studien-ID-Nummern\n- P50AT000066-01P1 (US NIH Stipendium/Vertrag)\n- P50AT000066-01 (US NIH Stipendium/Vertrag)\nDiese Informationen wurden ohne \u00c4nderungen direkt von der Website\n[clinicaltrials.gov](https://clinicaltrials.gov) abgerufen. Wenn Sie Ihre Studiendaten \u00e4ndern, entfernen oder aktualisieren m\u00f6chten, wenden Sie sich bitte an [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Sobald eine \u00c4nderung auf [clinicaltrials.gov](https://clinicaltrials.gov) implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .\nKlinische Studien zur Multiple Sklerose\n-\nNCT06095271Noch keine Rekrutierung\n[MultiSCRIPT-Zyklus 1: Personalisierte Medizin bei Multipler Sklerose \u2013 Pragmatische Plattformstudie eingebettet in das SMSC](https://ichgcp.net/de/clinical-trials-registry/NCT06095271)Multiple Sklerose, schubf\u00f6rmig remittierend\n-\nNCT06094855Rekrutierung\n-\nNCT06090084Noch keine Rekrutierung\n-\nNCT06090305Noch keine Rekrutierung\n-\nNCT06083753Noch keine Rekrutierung\n[Studie zur Bewertung der Sicherheit und Wirksamkeit von PIPE-307 bei Patienten mit schubf\u00f6rmig remittierender Multipler Sklerose (VISTA)](https://ichgcp.net/de/clinical-trials-registry/NCT06083753)Schubf\u00f6rmig remittierende Multiple Sklerose\n-\nNCT06082752Noch keine Rekrutierung\n-\nNCT06083194Noch keine Rekrutierung\n-\nNCT06081348Noch keine Rekrutierung\n[Sertralin vs. Placebo bei der Behandlung von Angstzust\u00e4nden bei Kindern und Jugendlichen mit neurologischen Entwicklungsst\u00f6rungen (CALM)](https://ichgcp.net/de/clinical-trials-registry/NCT06081348)Angstst\u00f6rungen | Generalisierte Angstst\u00f6rung | Angst | Tuber\u00f6se Sklerose | ADHS | Neuroentwicklungsst\u00f6rungen | Autismus-Spektrum-St\u00f6rung | Fragiles X-Syndrom | Soziale Angst | Soziale Angstst\u00f6rung\n-\nNCT06075472Rekrutierung\n-\nNCT06072287RekrutierungLeberkrankheiten | Herzkrankheiten | Herzfehler | Streicheln | Zerebrovaskul\u00e4re Erkrankungen | Epilepsie | Schmerzen | Multiple Sklerose | Hypertonie | Fettleibigkeit\nKlinische Studien zur Ginkgo biloba\n-\nNCT04846179Noch keine Rekrutierung\n-\nNCT04192656RekrutierungObstruktive Schlafapnoe | Pl\u00f6tzlicher H\u00f6rverlust\n-\nNCT02465749Noch keine Rekrutierung\n-\nNCT05591144AbgeschlossenH\u00f6rverlust, sensorineural | Tinnitus, subjektiv\n-\nNCT04121728Aktiv, nicht rekrutierend\n[Modulation der Aufmerksamkeit im ereignisbezogenen Potenzial (ERPs) als Marker f\u00fcr fr\u00fchen kognitiven R\u00fcckgang von Ginkgo Biloba (AgilGinkgo)](https://ichgcp.net/de/clinical-trials-registry/NCT04121728)Kognitive Leistungsf\u00e4higkeit | Funktionsf\u00e4higkeit | Subjektiver kognitiver R\u00fcckgang | Altersbedingter kognitiver R\u00fcckgang\n-\nNCT04448535Abgeschlossen\n-\nNCT05398874Abgeschlossen\n-\nNCT05258123Abgeschlossen\n-\nNCT01637168Zur\u00fcckgezogen\n-\nNCT01246804Abgeschlossen\n[Der Einfluss von GINkGo Biloba auf die Pharmakokinetik des UGT-Substrats raltEgraviR (INGWER) (GINGER)](https://ichgcp.net/de/clinical-trials-registry/NCT01246804)Depression | HIV-Infektionen | Leichte kognitive Einschr\u00e4nkung", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/de", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/de/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/de/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/de/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/de/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/de/ich-e-group-of-guidelines", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/eu-clinical-trials-registry", "https://ichgcp.net/de/pharma-list", "https://ichgcp.net/de/labs", "https://ichgcp.net/de/service-companies", "https://ichgcp.net/de/events", "https://ichgcp.net/de/clinical-trials-registry/publications", "https://ichgcp.net/de/clinical-trials-registry/researchers", "https://ichgcp.net/de/cra-jobs", "https://ichgcp.net/de/publications", "https://ichgcp.net/de/news", "https://ichgcp.net/clinical-trials-registry/NCT00010842", "https://telegram.me/share/url?url=https://ichgcp.net/de/clinical-trials-registry/NCT00010842&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/de/clinical-trials-registry/NCT00010842", "https://ichgcp.net/de", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=National%20Center%20for%20Complementary%20and%20Integrative%20Health%20%28NCCIH%29", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Multiple%20Sclerosis", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Ginkgo%20biloba", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Alpha-lipoic%20acid", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Vitamin%20E%2FSelenium", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Essential%20fatty%20acids", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=National%20Center%20for%20Complementary%20and%20Integrative%20Health%20%28NCCIH%29", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pathologic%20Processes", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Nervous%20System%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Immune%20System%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Demyelinating%20Autoimmune%20Diseases%2C%20CNS", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Autoimmune%20Diseases%20of%20the%20Nervous%20System", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Demyelinating%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Autoimmune%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Multiple%20Sclerosis", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Sclerosis", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Physiological%20Effects%20of%20Drugs", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Molecular%20Mechanisms%20of%20Pharmacological%20Action", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Protective%20Agents", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Trace%20Elements", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Micronutrients", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Vitamins", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Antioxidants", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Vitamin%20B%20Complex", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Vitamin%20E", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Thioctic%20Acid", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Selenium", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/de/clinical-trials-registry/NCT06095271", "https://ichgcp.net/de/clinical-trials-registry/NCT06094855", "https://ichgcp.net/de/clinical-trials-registry/NCT06090084", "https://ichgcp.net/de/clinical-trials-registry/NCT06090305", "https://ichgcp.net/de/clinical-trials-registry/NCT06083753", "https://ichgcp.net/de/clinical-trials-registry/NCT06082752", "https://ichgcp.net/de/clinical-trials-registry/NCT06083194", "https://ichgcp.net/de/clinical-trials-registry/NCT06081348", "https://ichgcp.net/de/clinical-trials-registry/NCT06075472", "https://ichgcp.net/de/clinical-trials-registry/NCT06072287", "https://ichgcp.net/de/clinical-trials-registry/NCT04846179", "https://ichgcp.net/de/clinical-trials-registry/NCT04192656", "https://ichgcp.net/de/clinical-trials-registry/NCT02465749", "https://ichgcp.net/de/clinical-trials-registry/NCT05591144", "https://ichgcp.net/de/clinical-trials-registry/NCT04121728", "https://ichgcp.net/de/clinical-trials-registry/NCT04448535", "https://ichgcp.net/de/clinical-trials-registry/NCT05398874", "https://ichgcp.net/de/clinical-trials-registry/NCT05258123", "https://ichgcp.net/de/clinical-trials-registry/NCT01637168", "https://ichgcp.net/de/clinical-trials-registry/NCT01246804", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Medical%2BSchool%2BBerlin", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Centre%2Bde%2Bla%2Bmain%2B-%2BCHUV", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Sismanoglio%2B-%2BAmalia%2BFleming%2BGeneral%2BHospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=LiveRNA%2BTherapeutics%2BInc.", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Wei%2BZhao", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Dicle%2BUniversity%2BSchool%2Bof%2BMedicine%252C%2BDiyarbakir%252C%2BTurkey", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Pirkanmaa%2BHospital%2BDistrict", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Middlesex%2BUniversity%2BLondon", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Nanjing%2BPLA%2BGeneral%2BHospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Deutsche%2BGesellschaft%2Bf%25C3%25BCr%2BAllgemein-%2Bund%2BViszeralchirurgie", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Invasive%2BDuctal%2BBreast%2BCarcinoma%2BWith%2BPredominant%2BIntraductal%2BComponent", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Multi-kinase%2BInhibitors", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Dexmedetomidine%252C%2BEsketamine%252C%2BPostoperative%2BPain%2Band%2BRecovery%2BQuality", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Minimal%2BChange%2BNephropathy", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Intra-ocular%2BPressure", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Tinea%2Bcruris", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Mothers", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Optic%2BNerve", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Musculoskeletal%2BDisorder%2Bof%2Bthe%2BNeck", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Shouldersurgery", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=FEIBA%2Band%2BNovoSeven", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=HM781-36B%2Btablets", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Ketamine%2Bhigh-dose", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=bardoxolone%2Bmethyl", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Chinese%2Bherb%2Bmedicine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=CD30.CAR-T", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Lyndiol%25C2%25AE", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Approved%2BICIs", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=d-amphetamine%2Bsulfate", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=0.3%2525%2Bhyaluronic%2Bacid%2Beye%2Bdrops", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/de/cro-list/country/cambodia", "https://ichgcp.net/de/cro-list/country/canada", "https://ichgcp.net/de/cro-list/country/egypt", "https://ichgcp.net/de/cro-list/country/france", "https://ichgcp.net/de/cro-list/country/israel", "https://ichgcp.net/de/cro-list/country/kazakhstan", "https://ichgcp.net/de/cro-list/country/latvia", "https://ichgcp.net/de/cro-list/country/malta", "https://ichgcp.net/de/cro-list/country/papua_new_guinea", "https://ichgcp.net/de/cro-list/country/serbia", "https://ichgcp.net/de/cro-list/country/thailand", "https://ichgcp.net/de/cro-list/country/togo", "https://ichgcp.net/de/cro-list/country/trinidad_tobago", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/cro-list/country/colombia/company/applied_healthcare_resource_management_ahrm", "https://ichgcp.net/de/cro-list/country/colombia/company/namsa", "https://ichgcp.net/de/cro-list/country/colombia/company/intrials", "https://ichgcp.net/de/cro-list/country/colombia/company/egcp_sa_excellence_in_good_clinical_practice", "https://ichgcp.net/de/cro-list/country/colombia/company/nergy_health_research", "https://ichgcp.net/de/cro-list/country/colombia/company/clinlogix", "https://ichgcp.net/de/cro-list/country/colombia/company/coltrials_sas", "https://ichgcp.net/de/cro-list/country/colombia/company/labcorp_drug_development", "https://ichgcp.net/de/cro-list/country/colombia/company/sgs", "https://ichgcp.net/de/cro-list/country/colombia/company/psi", "https://ichgcp.net/de/cro-list/country/colombia", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/de", "https://ichgcp.net/de/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/de/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/de/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/de/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/de/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/pharma-list", "https://ichgcp.net/de/labs", "https://ichgcp.net/de/service-companies", "https://ichgcp.net/de/cra-jobs", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/eu-clinical-trials-registry", "https://ichgcp.net/de/publications", "https://ichgcp.net/de/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/de/sitemap", "https://ichgcp.net/de/contact-us", "https://ichgcp.net/de/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT00010842", "https://ichgcp.net/de/clinical-trials-registry/NCT00010842", "https://ichgcp.net/clinical-trials-registry/NCT00010842", "https://ichgcp.net/es/clinical-trials-registry/NCT00010842", "https://ichgcp.net/fr/clinical-trials-registry/NCT00010842", "https://ichgcp.net/it/clinical-trials-registry/NCT00010842", "https://ichgcp.net/hu/clinical-trials-registry/NCT00010842", "https://ichgcp.net/nl/clinical-trials-registry/NCT00010842", "https://ichgcp.net/no/clinical-trials-registry/NCT00010842", "https://ichgcp.net/pl/clinical-trials-registry/NCT00010842", "https://ichgcp.net/pt/clinical-trials-registry/NCT00010842", "https://ichgcp.net/fi/clinical-trials-registry/NCT00010842", "https://ichgcp.net/sv/clinical-trials-registry/NCT00010842", "https://ichgcp.net/cs/clinical-trials-registry/NCT00010842", "https://ichgcp.net/ru/clinical-trials-registry/NCT00010842", "https://ichgcp.net/ja/clinical-trials-registry/NCT00010842", "https://ichgcp.net/zh/clinical-trials-registry/NCT00010842", "https://ichgcp.net/ko/clinical-trials-registry/NCT00010842", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}